Cargando…
It’s TIME for a biomarker-driven approach to cancer immunotherapy
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986195/ https://www.ncbi.nlm.nih.gov/pubmed/27532018 http://dx.doi.org/10.1186/s40425-016-0147-8 |
| _version_ | 1782448164312186880 |
|---|---|
| author | Emens, Leisha A. |
| author_facet | Emens, Leisha A. |
| author_sort | Emens, Leisha A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4986195 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-49861952016-08-17 It’s TIME for a biomarker-driven approach to cancer immunotherapy Emens, Leisha A. J Immunother Cancer Commentary BioMed Central 2016-08-16 /pmc/articles/PMC4986195/ /pubmed/27532018 http://dx.doi.org/10.1186/s40425-016-0147-8 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Commentary Emens, Leisha A. It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title | It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title_full | It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title_fullStr | It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title_full_unstemmed | It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title_short | It’s TIME for a biomarker-driven approach to cancer immunotherapy |
| title_sort | it’s time for a biomarker-driven approach to cancer immunotherapy |
| topic | Commentary |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4986195/ https://www.ncbi.nlm.nih.gov/pubmed/27532018 http://dx.doi.org/10.1186/s40425-016-0147-8 |
| work_keys_str_mv | AT emensleishaa itstimeforabiomarkerdrivenapproachtocancerimmunotherapy |